The global Recurrent Atrial Fibrillation Market is expected to reach USD 25.93 Billion by 2027, according to a new report by Emergen Research. The increasing incidence of recurrent atrial fibrillation is majorly associated with recurrent paroxysmal atrial fibrillation patients, with the occurrence of a family history of AFib, high blood pressure, sleep apnea, overuse of stimulants, alcohol consumption, obesity, thyroid disorders, diabetes, lung disease, severe infections, and stress.
Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years.
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/71
Moreover, healthcare experts from the University of Pennsylvania have estimated that patients admitted to intensive care units for COVID-19 treatment are more likely to suffer from arrhythmia and atrial fibrillation. This would be alarming for cardiac patients and would lead to increased sales of atrial fibrillation associated drugs.
Emergen Research have segmented the global Recurrent Atrial Fibrillation Market on the basis of product, application, end-uses, and region:
Product Outlook (Revenue, USD Billion; 2017-2027)
- Surgical Devices
- Maze Surgery
- Catheter Ablation
- Radiofrequency Catheter Ablation
- Conventional RF Ablation Catheters
- Irrigated-tip RF Ablation Catheters
- Microwave Based Catheter Ablation
- Laser Based Catheter Ablation
- Navigational Advanced Mapping Accessories
- Non-Surgical Devices
- Electric Cardioversion
- EP Ablation Catheters
- EP Diagnostic Catheter
- Conventional Diagnostic Catheters
- Fixed Diagnostic Catheters
- Steerable Diagnostic Catheters
- Advanced Diagnostic Catheters
- Mapping and Recording Systems
- Cardiac Monitors or Loop Recorders
- Access Devices
- Left Atrial Appendage and Closure Devices
- Intracardiac Echocardiography (ICE) Systems
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- Edoxaban (Savaysa)
- Warfarin (Coumadin)
Application Outlook (Revenue, USD Billion; 2017-2027)
- EP Ablation
- Surgical Cardiac
End Users Outlook (Revenue, USD Billion; 2017-2027)
- Cardiac Centers
- Ambulatory Care Centers
Some Key Highlights from the Report
In January 2019, Abbott announced the acceptance of the TactiCath Touch Force Ablation Catheter by the FDA. Such winning tactics of leading companies in the market for atrial fibrillation products are often adopted by national and local companies.
The prevalence of AFib ranges between 2.7 million and 6.1 million in the U.S. alone and is estimated to reach 12.1 million by the year 2030, according to the statistics of the Center for Disease Control. Similar incidence rates are observed in other regions as well, indicating potential growth in the target industry.
Recently, in December 2019, the opening generic version of the blood thinner Eliquis received approval by the U.S. FDA. The drug is anticipated to provide quality treatment alternatives at affordable prices, especially for recurrent AFib patients, by reducing the risk of recurrence.
The device type product segment is estimated to reach USD 5.88 billion by the year 2027 at a CAGR of 14.0% during the forecast period.
Electrophysiology can estimate the electrical activity of the heart while the catheter ablation technique is used to treat arrhythmia of specific types. Electrophysiology is regarded as the most effective method for recurrent episodes of atrial fibrillation after drugs remain ineffective to the patient’s body.
Atrial fibrillation diagnosis includes screening as regular care in elderly patients and patients with other risk factors. Diagnostic testing also includes an ECG or EKG heart’s electrical activity. The presence of advanced software based ECG monitoring devices would improve the quality of treatment for recurrent atrial fibrillation patients.
Key participants contributing significant market shares in the industry growth includes Johnson Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.
Request customization of the report: https://www.emergenresearch.com/request-for-customization/71
The report offers a comprehensive overview of the competitive landscape and covers company profiles, production and manufacturing capacity, product portfolio, expansion strategies, and business initiatives such as mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches and brand promotions among others.
1.1 Research Scope
1.2 Key Recurrent Atrial Fibrillation market segments
1.3 Major players
1.4 Market analysis by product
1.5 Market analysis by application
1.6 Report timeline
Global Growth Trends
2.1 Global Recurrent Atrial Fibrillation market size
2.2 Latest Recurrent Atrial Fibrillation market trends
2.3 Key growth trends
3.1 Global Recurrent Atrial Fibrillation market key players
3.2 Global Recurrent Atrial Fibrillation size by manufacturers
3.3 Products of major players
3.4 Entry barriers in the Recurrent Atrial Fibrillation market
3.5 Mergers, acquisitions, joint ventures, and strategic alliances
The global Recurrent Atrial Fibrillation market has been categorized on the basis of key geographical regions into North America, Asia Pacific, Europe, Latin America, and Middle East Africa. It evaluates the presence of the global Recurrent Atrial Fibrillation market in the major regions with regards to market share, market size, revenue contribution, sales network and distribution channel, and other key elements.
Key questions addressed in the report:
What are the key factors driving the global Recurrent Atrial Fibrillation market?
Who are the key manufacturers in this market space?
Who are the distributors, traders and dealers of this market?
What are the market opportunities and risks affecting the performance of the vendors in the global Recurrent Atrial Fibrillation market?
What are the sales and revenue estimations for the top manufacturers in this market over the projected timeline?
Read More: https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market
oncolytic virus therapies market
usb flashdrives market
healthcare internet of things security market
crispr/cas 9 technology market
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
Facebook | LinkdIn | Twitter | Blogs